See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated

Diabetes and Actos Article Archives

January 2014

New Type 2 Drugs Change Treatment Decisions

Metformin, the cornerstone in treating type 2 diabetes, saw an increase in usage among type 2s from 23 percent of that population in 1997 to 53 percent in 2012. But that increase has since plateaued due to the introduction of additional drugs that target insulin secretion and glucose regulation.

comments 0 comments - Posted Jan 4, 2014

July 2013

Diabetes Patients on Insulin Sensitizers Run Lower PAD Risk

Insulin sensitizers--drugs that increase sensitivity to insulin such as Avandia and Actos--could help lessen the risk of peripheral arterial disease (PAD) for those with type 2 diabetes, according to a new study.

comments 1 comment - Posted Jul 5, 2013

June 2013

FDA Panelists Vote to Ease Up on Avandia

A significant majority-20 of 26 members attending a combined meeting of FDA advisory committees-has voted to modify or remove the current restrictive label and distribution regulations affecting the type 2 drug Avandia.

comments 0 comments - Posted Jun 9, 2013

August 2012

US Sale of Generic Actos Gets FDA Nod

The Food and Drug Administration has approved US sale of generic pioglitazone (trade name Actos) for the treatment of type 2 diabetes. Actos, originally developed and trademarked by Takeda Pharmaceuticals, works by decreasing insulin resistance in type 2 patients. The prescription drug, which belongs to the class of drugs known as thiazolidinediones (TZDs), has enjoyed great commercial success in the United States since its introduction in 1999, posting estimated sales last year of $2.7 billion.

comments 0 comments - Posted Aug 27, 2012

May 2011

Cheaper Generic Medication for Lipitor, Actos and Plavix

A recent article in the Chicago Tribune reports that patients using Lipitor, Actos, or Plavix may start enjoying savings of up to 90 percent as patents on those drugs expire. The three drugs comprise a significant percentage of the $300 billion brand-name U.S. pharmaceutical market, according to the Tribune.

comments 2 comments - Posted May 27, 2011

September 2010

FDA Significantly Restricts Access to the Diabetes Drug Avandia

The U.S. Food and Drug Administration today announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.

comments 0 comments - Posted Sep 23, 2010

July 2009

ID Genetic Markers That Could Improve Effectiveness of Diabetes Therapies

Scientists have identified five genetic biomarkers that predict how well a type 2 patient will respond to the drug Actos. Their work could be the first step toward a system that would allow doctors to predetermine which drugs will best help each person with diabetes. 

comments 0 comments - Posted Jul 3, 2009

April 2009

Long-Acting Byetta Tops Two Other Diabetes Drugs in Direct Comparison

Results from DURATION-2, a 26-week test comparing the diabetic drugs Januvia, Actos, and experimental long-acting Byetta (Byetta LAR) show that Byetta produced lower A1c's and more weight loss than the other two drugs.

comments 5 comments - Posted Apr 15, 2009

March 2009

Insulin For Type 2 Diabetes: Who, When, And Why?

Physicians who treat people with type 2 diabetes face difficult choices when selecting the best medical therapy for each patient. The decision process is further complicated by the fact that because type 2 diabetes is a progressive disease, therapeutic agents that were initially successful may fail five or ten years later.

comments 159 comments - Posted Mar 20, 2009

December 2008

Women Have Double the Fracture Risk with Avandia and Actos

Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.

comments 0 comments - Posted Dec 22, 2008

October 2007

Black Box Warning For Actos and Avandia

The FDA has spoken: the heart risk warnings on labels of Avandia (rosiglitazone) and Actos (pioglitazone) will now be surrounded by an emphatic black outline known as a black box. Black boxes will also be added to the warnings on Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepiride).

comments 3 comments - Posted Oct 31, 2007

Actos and Avandia Cost Plenty

According to Greek researchers, Actos and Avandia were behind a tripling of the cost of medicines used to treat Athenians with type 2 diabetes over the past eight years.

comments 0 comments - Posted Oct 10, 2007

Actos and Avandia: New Heart Risk Studies

The September 2007 Journal of the American Medical Association (JAMA) has published two new studies, one a meta-analysis of Avandia (rosiglitazone) and the other a meta-analysis of Actos (pioglitazone).

comments 0 comments - Posted Oct 5, 2007

August 2007

The Latest About Avandia and Actos

On July 30, 2007, a Food and Drug Administration (FDA) panel voted 22 to 1 to keep Avandia on the market, right after agreeing by a vote of 20 to 3 that Avandia does increase heart risks. Now the FDA will decide what kind of warning should appear on the Actos and Avandia labels. It has already called for a black box warning, the sternest possible, on Avandia.

comments 0 comments - Posted Aug 1, 2007

July 2007

Amid Accusatory Debate, FDA Puts Black Box Warning on Avandia and Actos

In a congressional hearing on June 13, 2007, the Food and Drug Administration (FDA) revealed that it has called for a black box warning, the sternest possible, on both Actos and Avandia.

comments 0 comments - Posted Jul 12, 2007

May 2007

Updated: Analysis Associates Avandia With Greater Risk of Heart Attack

Analysis of several recent studies indicates that Avandia (rosiglitazone), a type 2 diabetes medication that's been taken by more than six million people worldwide, is associated with a 43 percent increased risk of heart attack and with a borderline-significant increased risk of heart attack-related death.

comments 0 comments - Posted May 31, 2007

September 2006

Oral Meds Research

Starlix Found to Reduce Liver Fat

comments 0 comments - Posted Sep 1, 2006

April 2006

Actos Alone or Combined With Oral Meds Improves Your Patient’s BGs and Lipids

New Zealand researchers say that in clinical trials of people with type 2 diabetes, Actos as stand-alone therapy or in combination with metformin, repaglinide, insulin or a sulphonylurea induced “both long- and short-term improvements in [blood glucose] control and serum lipid profiles.”

comments 0 comments - Posted Apr 1, 2006

January 2006

Is Pargluva On the Ropes?

It was the belle of the ball at last summer’s ADA Scientific Sessions in San Diego. Now it appears that muraglitazar (Pargluva) is clinging to life after a scathing report recently published by the Journal of the American Medical Association.

comments 0 comments - Posted Jan 1, 2006

November 2005

ACTOplus Met Approved by the FDA for Type 2 Diabetes

In August 2005, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) had approved ACTOplus Met for the treatment of type 2 diabetes.

comments 0 comments - Posted Nov 1, 2005

October 2005

Actos

Actos (pioglitazone HCl) is an oral agent for type 2 diabetes belonging to the thiazolidinedione (TZD) class of drugs. TZDs help lower insulin resistance, a core dysfunction in people with type 2. They act by helping the body use its available amounts of insulin more effectively. Actos is known as an “insulin sensitizer” because it directly targets insulin resistance, a condition in which the body cannot use the insulin it produces efficiently.

comments 0 comments - Posted Oct 1, 2005

September 2005

Actos May Improve Heart Safety in Type 2s

Actos, an insulin sensitizer in the glitazone class of type 2 oral diabetes medications, was found to reduce carotid artery intima-media thickness (IMT) as well as insulin resistance in a German study.

comments 0 comments - Posted Sep 1, 2005

July 2005

Byetta Now Available for Type 2s

“People who are no longer successful on oral agents can now add Byetta [exenatide] instead of insulin,” says Anne Peters, MD, director of the USC Clinical Diabetes Programs.

comments 1 comment - Posted Jul 1, 2005

November 2002

Weighing the Evidence

A shift in fat distribution from visceral (the internal abdominal area) to subcutaneous (under the skin) could be the reason the insulin sensitizer Actos (pioglitazone) helps to lower blood-glucose levels in people with insulin resistance.

comments 0 comments - Posted Nov 1, 2002

Weighing the Evidence: Blood Glucose Levels Decrease with Insulin Sensitizer Despite Weight Increase

A shift in fat distribution from visceral (the internal abdominal area) to subcutaneous (under the skin) could be the reason the insulin sensitizer Actos (pioglitazone) helps to lower blood glucose levels in people with insulin resistance.

comments 0 comments - Posted Nov 1, 2002

August 2002

A Research Extravaganza

Once again, Diabetes Health has read through more than 2,500 abstracts of research presented at the American Diabetes Association's annual Scientific Sessions and selected a few of the more interesting ones to pass along to you as part of our annual "Research Extravaganza" feature.

comments 0 comments - Posted Aug 1, 2002

September 1999

Avandia and ACTOS Hit The Ground Running—Rezulin Competitors Show No Liver Toxicity in Clinical Trials

Two new drugs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. In clinical trials, Avandia (rosiglitazone maleate) and ACTOS (pioglitazone hydrochloride) lowered blood sugars an average of 76 mg/dl and 95 mg/dl respectively, when compared to a placebo.

comments 0 comments - Posted Sep 1, 1999

July 1999

New Drug for Type 2 Diabetes Shows No Liver Damage

In clinical trials, patients taking ACTOS demonstrated no elevation of their liver enzymes when compared to patients taking a placebo.

comments 0 comments - Posted Jul 1, 1999

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.